In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )
There are fewer than 1 million enrolled individuals in plans with coverage, less than 5% of total Marketplace enrollment
No significant abnormalities in behavior, weight, or organ histology were observed after standard experimental administration (2)
& Robertson, R
Its not advised for diabetics to yo-yo with the medication either, with frequent fluctuations being linked to heart disease and some forms of cancer
Pregnancy LACARNIT INJECTION 5ML should be used during pregnancy only if clearly needed and prescribed by your doctor